miRNA | AVG Ct | 2[-AvgΔ(Ct)] | Ratio Patient/Control | |||
---|---|---|---|---|---|---|
Control | Patient | Control | Patient | |||
26.00 | 25.04 | 0.136139 | 0.203892 | 0.025721 | 1.4977 | |
26.80 | 24.68 | 0.078435 | 0.26217 | 0.000003 | 3.3425 |
Patient Group ( | ||
---|---|---|
HLA-B27 | negative positive | 23 (46.0) 27 (54.0) |
ESR | median (min-max) mean+SD | 17 (2-59) 21.36±15.51 |
Symptom duration (years) | median (min-max) mean+SD | 5 (1-25) 6.60±5.08 |
BASDAI | median (min-max) mean±SD | 2.5 (0-8) 2.75±2.03 |
BASF | median (min-max) mean+SD | 5(5-12) 5.36±1.19 |
BASMI | median (min-max) mean+SD | 1 (0-9.8) 1.55±1.93 |
median (min-max) mean±SD | 24.1 (21.4-30.5) 24.68±2.06 | |
median (min-max) mean+SD | 24.2 (21.6-35.8) 25.10±3.11 | |
Control Group ( | ||
median (min-max) mean±SD | 26.4 (22.45-34.7) 26.88±2.88 | |
median (min-max) mean+SD | 25.4(21.28-33.7) 26.02±2.71 |
Patient Group ( | ||||
---|---|---|---|---|
r Pearson correlation coefficient. | p Value | r Spearman’s correlation coefficient. | p Value | |
Age (years) | 0.047 | 0.746 | 0.126 | 0.384 |
ESR | -0.070 | 0.641 | -0.081 | 0.589 |
Symptom duration (years) | -0.184 | 0.200 | -0.172 | 0.233 |
BASDAI | -0.268 | 0.060 | -0.266 | 0.062 |
BASFI | -0.026 | 0.861 | -0.114 | 0.447 |
BASMI | 0.062 | 0.671 | 0.229 | 0.110 |
Descriptive Characteristics ( | ||
---|---|---|
Age (years) | median (min-max) | 37(18-60) |
mean±SD | 37.24±9.42 | |
Gender | females | 58 (58.0) |
males | 42 (42.0) |